Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation

This study has been completed.
Sponsor:
Collaborator:
University Hospital Heidelberg
Information provided by (Responsible Party):
Christoph Stephan, Johann Wolfgang Goethe University
ClinicalTrials.gov Identifier:
NCT01168167
First received: July 21, 2010
Last updated: March 22, 2016
Last verified: March 2016